LFVN Lifevantage

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against LifeVantage Corporation - LFVN

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of LifeVantage Corporation (NASDAQ: LFVN) resulting from allegations that LifeVantage may have issued materially misleading business information to the investing public.

On September 13, 2016, LifeVantage disclosed that it was delaying the release of its fourth quarter and fiscal year 2016 financial results. The delay is due to LifeVantage’s review of its sales into certain international markets and the revenue and income tax and the associated accruals. On this news, shares of LifeVantage fell sharply during intraday trading on September 14, 2016.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by LifeVantage investors. If you purchased shares of LifeVantage on or before September 13, 2016, please visit the firm’s website at http://www.rosenlegal.com/cases-952.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
14/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lifevantage

 PRESS RELEASE

LifeVantage Declares Quarterly Dividend

LifeVantage Declares Quarterly Dividend SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company’s Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid March 16, 2026 to all stockholders of record at the close of business on March 2, 2026. About LifeVantage Corporation LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer...

 PRESS RELEASE

LifeVantage Announces Planned Retirement of Steve Fife and CEO Success...

LifeVantage Announces Planned Retirement of Steve Fife and CEO Succession Plan SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level, today announced that after nine years at LifeVantage, Steve Fife, President, Chief Executive Officer and a member of the Board of Directors (the “Board”), has decided to retire in April, 2026. Fife will continue in his role as President and Chief Executive Officer during the transition period to ensure business continuity through his re...

 PRESS RELEASE

LifeVantage Announces Financial Results for the Second Quarter of Fisc...

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026 Announces New $60 Million Share Repurchase Authorization SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2025. Second Quarter Fiscal 2026 Summary*: Revenue was $48.9 million, a decrease of 27.8% from the prior year period. Revenue was up 2.9% sequentially from the fir...

 PRESS RELEASE

LifeVantage to Announce Second Quarter Fiscal Year 2026 Results on Feb...

LifeVantage to Announce Second Quarter Fiscal Year 2026 Results on February 4, 2026 SALT LAKE CITY, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its second quarter ended December 31, 2025, after the stock market closes on Wednesday, February 4, 2026. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors inter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch